HLB's Cholangiocarcinoma Drug Candidate Designated for FDA Priority Review
Review Period Shortened to 6 Months
Approval Decision Expected by September
HLB's new drug candidate for cholangiocarcinoma has been designated for Priority Review by the U.S. Food and Drug Administration (FDA) and has entered the formal review process. The approval decision is expected to be made by the end of September 2026.
HLB announced on March 30 that its U.S. subsidiary, Elevar Therapeutics (hereinafter "Elevar"), received notice from the FDA on March 27 (local time) that the agency has begun the formal review of the new drug application for "lirafugratinib" as a second-line treatment for cholangiocarcinoma with FGFR2 fusion and rearrangement.
The FDA has designated this application for Priority Review. As a result, the typical review period of 10 months has been shortened to approximately 6 months. The final decision on approval is expected by September 27, 2026.
In clinical trials, lirafugratinib achieved an objective response rate of 47%. This is higher than the rates for existing FGFR inhibitors, such as pemigatinib (36%) and futibatinib (42%). The company also stated that, in terms of safety, the drug could be managed at a controllable level through dose adjustment.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Elevar plans to focus on preparing for regulatory approval and commercial launch, taking this Priority Review designation as an opportunity. The company also aims to accelerate development by concurrently expanding ongoing clinical trials to additional cancer types.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.